@article{3105165,
    title = "The Greek study in the effects of colchicine in COvid-19 complications prevention (GRECCO-19 study): Rationale and study design",
    author = "Deftereos, S.G. and Siasos, G. and Giannopoulos, G. and Vrachatis, D.A. and Angelidis, C. and Giotaki, S.G. and Gargalianos, P. and Giamarellou, H. and Gogos, C. and Daikos, G. and Lazanas, M. and Lagiou, P. and Saroglou, G. and Sipsas, N. and Tsiodras, S. and Chatzigeorgiou, D. and Moussas, N. and Kotanidou, A. and Koulouris, N. and Oikonomou, E. and Kaoukis, A. and Kossyvakis, C. and Raisakis, K. and Fountoulaki, K. and Comis, M. and Tsiachris, D. and Sarri, E. and Theodorakis, A. and Martinez-Dolz, L. and Sanz-Sánchez, J. and Reimers, B. and Stefanini, G.G. and Cleman, M. and Filippou, D. and Olympios, C.D. and Pyrgakis, V.N. and Goudevenos, J. and Hahalis, G. and Kolettis, T.M. and Iliodromitis, E. and Tousoulis, D. and Stefanadis, C.",
    journal = "Ελληνική καρδιολογική επιθεώρηση",
    year = "2020",
    volume = "61",
    number = "1",
    pages = "42-45",
    publisher = "Hellenic Cardiological Society",
    issn = "1011-7970",
    doi = "10.1016/j.hjc.2020.03.002",
    keywords = "azithromycin;  C reactive protein;  colchicine;  troponin;  antirheumatic agent;  colchicine;  troponin, ageusia;  anosmia;  Article;  artificial ventilation;  blood oxygen tension;  clinical trial;  controlled study;  coronavirus disease 2019;  coughing;  fatigue;  human;  loading drug dose;  lung function test;  mortality;  open study;  prospective study;  randomized controlled trial;  reverse transcription polymerase chain reaction;  sore throat;  Betacoronavirus;  blood;  complication;  Coronavirus infection;  heart disease;  isolation and purification;  laboratory technique;  pandemic;  pathophysiology;  procedures;  randomized controlled trial (topic);  symptom assessment;  virus pneumonia, Antirheumatic Agents;  Betacoronavirus;  Clinical Laboratory Techniques;  Colchicine;  Coronavirus Infections;  Heart Diseases;  Humans;  Pandemics;  Pneumonia, Viral;  Randomized Controlled Trials as Topic;  Symptom Assessment;  Troponin",
    abstract = "Objective: Colchicine has been utilized safely in a variety of cardiovascular clinical conditions. Among its potential mechanisms of action is the non-selective inhibition of NLRP3 inflammasome which is thought to be a major pathophysiologic component in the clinical course of patients with COVID-19. GRECCO-19 will be a prospective, randomized, open-labeled, controlled study to assess the effects of colchicine in COVID-19 complications prevention. Methods: Patients with laboratory confirmed SARS-CoV-2 infection (under RT PCR) and clinical picture that involves temperature >37.5 oC and at least two out of the: i. sustained coughing, ii. sustained throat pain, iii. Anosmia and/or ageusia, iv. fatigue/tiredness, v. PaO2<95 mmHg will be included. Patients will be randomised (1:1) in colchicine or control group. Results: Trial results will be disseminated through peer-reviewed publications and conference presentations. Conclusion: GRECCO-19 trial aims to identify whether colchicine may positively intervene in the clinical course of COVID-19. (ClinicalTrials.gov Identifier: NCT04326790). © 2020 Hellenic Society of Cardiology"
}